REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
Public ClinicalTrials.gov record NCT05973773. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and Safety of Zipalertinib Plus Chemotherapy Versus Chemotherapy Alone, in Patients With Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.
Study identification
- NCT ID
- NCT05973773
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 285 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 18, 2023 (Actual)
- Primary completion
- May 27, 2027 (Estimated)
- Completion
- May 27, 2027 (Estimated)
- Last update posted
- Jul 30, 2026
2023 – 2027
United States locations
- U.S. sites
- 9
- U.S. states
- 3
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Comprehensive Cancer Centers of Nevada - Henderson | Henderson | Nevada | 89052 | — |
| Comprehensive Cancer Centers of Nevada - Horizon Ridge Henderson | Henderson | Nevada | 89052 | — |
| Comprehensive Cancer Centers of Nevada - Southeast Henderson - Stephanie | Henderson | Nevada | 89074 | — |
| Comprehensive Cancer Centers of Nevada - Summerlin Medical Center II | Las Vegas | Nevada | 89144 | — |
| Comprehensive Cancer Centers of Nevada - Southwest | Las Vegas | Nevada | 89148 | — |
| Comprehensive Cancer Centers of Nevada - Central Valley - Twain | Las Vegas | Nevada | 89169 | — |
| Comprehensive Cancer Centers of Nevada - Northwest | Las Vegas | Nevada | 89218 | — |
| Gabrail Cancer and Research Center | Canton | Ohio | 44718 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 121 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05973773, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 30, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05973773 live on ClinicalTrials.gov.